Claudia Veronica Da Silva Crispim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Claudia Veronica Da Silva Crispim has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Nathaniel W. Snyder
Aging and Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA
40 shared publications - Adam Chatoff
Aging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, USA
39 shared publications - Aidan R. Cole
Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
39 shared publications - Amandine Amalric
Molecular and Cellular Oncogenesis Program, Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, PA, USA
39 shared publications - Apoorva Uboveja
Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, USA
39 shared publications - Baixue Yang
Department of Pharmacology and Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
39 shared publications
Latest Publications
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Miniaturized Reaction Platforms in Drug Discovery: from Synthesis to Direct-to-Biology Screening
The increasing demand for faster, more efficient drug discovery has exposed fundamental limitations in conventional design-make-test-analyze workflows, particularly regarding scalability, resource consumption, and reliance on purification-intensive processes. Miniaturized synthetic platforms have emerged not merely as a technical refinement, but as a paradigm shift integrating chemical synthesis and biological evaluation. This review examines miniaturization as a framework enabling the direct coupling of compound generation and biological screening, with emphasis on direct-to-biology strategies. A systematic assessment of the literature reveals convergence toward simplified, high-efficiency reaction formats compatible with automation and minimal purification. These platforms rely on a limited set of robust transformations, with amide coupling accounting for 42% of reported reactions, followed by multicomponent reactions (15%), click chemistry (14%), carbonyl-amine transformations (12%), and nucleophilic aromatic substitution (9%), while metal-catalyzed reactions remain underrepresented (3%). This distribution reflects a preference for high-yielding, operationally simple, and biocompatible reactions that tolerate crude conditions and enable direct screening. The integration of analytical and computational tools supports real‑time decision-making and accelerates structure-activity relationship exploration. Notably, efforts remain concentrated in oncology and infectious diseases, with a clear absence of applications targeting parasitic neglected tropical diseases. Collectively, these approaches redefine early-stage drug discovery by compressing timelines and reducing costs.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Miniaturized Reaction Platforms in Drug Discovery: from Synthesis to Direct-to-Biology Screening
The increasing demand for faster, more efficient drug discovery has exposed fundamental limitations in conventional design-make-test-analyze workflows, particularly regarding scalability, resource consumption, and reliance on purification-intensive processes. Miniaturized synthetic platforms have emerged not merely as a technical refinement, but as a paradigm shift integrating chemical synthesis and biological evaluation. This review examines miniaturization as a framework enabling the direct coupling of compound generation and biological screening, with emphasis on direct-to-biology strategies. A systematic assessment of the literature reveals convergence toward simplified, high-efficiency reaction formats compatible with automation and minimal purification. These platforms rely on a limited set of robust transformations, with amide coupling accounting for 42% of reported reactions, followed by multicomponent reactions (15%), click chemistry (14%), carbonyl-amine transformations (12%), and nucleophilic aromatic substitution (9%), while metal-catalyzed reactions remain underrepresented (3%). This distribution reflects a preference for high-yielding, operationally simple, and biocompatible reactions that tolerate crude conditions and enable direct screening. The integration of analytical and computational tools supports real‑time decision-making and accelerates structure-activity relationship exploration. Notably, efforts remain concentrated in oncology and infectious diseases, with a clear absence of applications targeting parasitic neglected tropical diseases. Collectively, these approaches redefine early-stage drug discovery by compressing timelines and reducing costs.
- Top Cited PapersOpen Access
- 18 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110602
Class I histone deacetylases catalyze lysine lactylation
- 18 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (10) , 110602
Top Cited PapersOpen AccessClass I histone deacetylases catalyze lysine lactylation
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
CRISPR screen results for human SKMEL28 cells
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
CRISPR screen results for human SKMEL28 cells
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
CRISPR screen results for mouse Yumm5.2 cells
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
CRISPR screen results for mouse Yumm5.2 cells
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
P16/CDKN2Alow cells are more sensitive to inhibitors of nucleotide metabolism. A, Table of inhibitors used in in vitro cell line studies. 1C metabolism = one carbon metabolism. B, SKMEL28 human melanoma cells were infected with lentivirus expressing a shRNA targeting p16 (shp16). shGFP was used as a control (shCont). Cells were treated with the indicated inhibitors and proliferation was assessed by crystal violet staining. IC50 and fold change (shp16 vs. shCont, FC) are indicated. Data from one of 2–3 independent experimental replicates are shown (n = 6). C, Increased drug sensitivity from DepMap data of cutaneous melanoma cell lines with high or low CDKN2A expression. Data are mean ± SD. t test. *, P < 0.05; **, P < 0.01.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
P16/CDKN2Alow cells are more sensitive to inhibitors of nucleotide metabolism. A, Table of inhibitors used in in vitro cell line studies. 1C metabolism = one carbon metabolism. B, SKMEL28 human melanoma cells were infected with lentivirus expressing a shRNA targeting p16 (shp16). shGFP was used as a control (shCont). Cells were treated with the indicated inhibitors and proliferation was assessed by crystal violet staining. IC50 and fold change (shp16 vs. shCont, FC) are indicated. Data from one of 2–3 independent experimental replicates are shown (n = 6). C, Increased drug sensitivity from DepMap data of cutaneous melanoma cell lines with high or low CDKN2A expression. Data are mean ± SD. t test. *, P < 0.05; **, P < 0.01.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Multiple CRISPR KO screens identify nucleotide metabolism genes that are selectively depleted in p16/CDKN2Alow cells. A, Schematic of our CRISPR screens. p16/Cdkn2a wildtype cells were infected with lentiviruses expressing shGFP control (shCont), shp16 (human), or shCdkn2a (mouse). Human and mouse isogenic cell pairs were infected with nucleotide-focused or whole metabolism-focused CRISPR gRNA libraries, respectively, at an MOI of <0.3. After 14 days in culture, gDNA was harvested and sequenced. Analysis of genes included in the “nucleotide metabolism signature” (Supplementary Table S1) identified multiple genes that are negatively enriched in shp16/shCdkn2a vs. shCont in human SKMEL28 (B) and mouse Yumm5.2 (C) melanoma cells. Raw data can be found in Supplementary Tables S3 and S4. D, Comparison of datasets and list of 31 common genes negatively enriched (log2 fold change <0) in the indicated analyses.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Multiple CRISPR KO screens identify nucleotide metabolism genes that are selectively depleted in p16/CDKN2Alow cells. A, Schematic of our CRISPR screens. p16/Cdkn2a wildtype cells were infected with lentiviruses expressing shGFP control (shCont), shp16 (human), or shCdkn2a (mouse). Human and mouse isogenic cell pairs were infected with nucleotide-focused or whole metabolism-focused CRISPR gRNA libraries, respectively, at an MOI of <0.3. After 14 days in culture, gDNA was harvested and sequenced. Analysis of genes included in the “nucleotide metabolism signature” (Supplementary Table S1) identified multiple genes that are negatively enriched in shp16/shCdkn2a vs. shCont in human SKMEL28 (B) and mouse Yumm5.2 (C) melanoma cells. Raw data can be found in Supplementary Tables S3 and S4. D, Comparison of datasets and list of 31 common genes negatively enriched (log2 fold change <0) in the indicated analyses.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
CRISPR KO library containing 128 genes comprising the nucleotide metabolism signature
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
CRISPR KO library containing 128 genes comprising the nucleotide metabolism signature
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Table S8 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Table S8 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Table S8 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Table S5 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
31 common genes identified in screens and publicly available data
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
31 common genes identified in screens and publicly available data
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Shp16 tumors are more sensitive to the antifolate methotrexate. A and B, SKMEL28 human melanoma cells were infected with lentivirus expressing a shRNA targeting GFP (shCont) or p16 (shp16). A total of 107 cells were subcutaneously implanted into athymic nude mice. Mice were treated with vehicle controls or methotrexate (MTX). Individual tumor growth curves in shp16 tumors (A) and shCont tumors (B). Shown are growth rates ± SE. Linear mixed-model group comparisons: shp16 versus shCont P < 0.001; shCont: MTX versus vehicle P = 0.734; shp16: MTX versus vehicle P = 0.031; (shp16: MTX vs. vehicle) versus (Control: vehicle vs. MTX) P = 0.002.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Shp16 tumors are more sensitive to the antifolate methotrexate. A and B, SKMEL28 human melanoma cells were infected with lentivirus expressing a shRNA targeting GFP (shCont) or p16 (shp16). A total of 107 cells were subcutaneously implanted into athymic nude mice. Mice were treated with vehicle controls or methotrexate (MTX). Individual tumor growth curves in shp16 tumors (A) and shCont tumors (B). Shown are growth rates ± SE. Linear mixed-model group comparisons: shp16 versus shCont P < 0.001; shCont: MTX versus vehicle P = 0.734; shp16: MTX versus vehicle P = 0.031; (shp16: MTX vs. vehicle) versus (Control: vehicle vs. MTX) P = 0.002.